• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, February 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Naltrexone helps HIV positive individuals reduce heavy alcohol use

Bioengineer by Bioengineer
August 7, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

New Haven, Conn. – Extended-release naltrexone — an injection that decreases heavy drinking in the general population when taken in conjunction with counseling — appears to help HIV-positive individuals reduce their number of heavy drinking days too, say Yale researchers.

This study was published online on Aug. 2 in AIDS and Behavior.

"While we know that patients with heavy alcohol use are less likely to take their medications for HIV, there is a paucity of interventions that target alcohol use to improve how patients take their medications," said Jennifer Edelman, M.D., first author and associate professor at the Yale School of Medicine. "Extended-release naltrexone is a medication that is safe and effective for patients living with HIV that can be delivered in HIV treatment settings that could potentially help this problem."

Conducted between April 2011 and February 2015, the trial involved 51 HIV positive individuals who exhibited heavy drinking and suboptimal (less than 95%) antiretroviral adherence. All the participants in the study received counseling. Researchers found that the extended-release naltrexone led to clinically and statistically significant decreases in the number of heavy drinking days for the participants.

However, the researchers saw no appreciable effect of the extended-release naltrexone, versus a placebo, on the adherence of HIV-positive individuals to their antiretroviral therapy regimens.

"We hope that these results will stimulate further research focused on enhancing the coupling of alcohol interventions with antiretroviral medication adherence interventions to improve both alcohol use and HIV related outcomes," said Lynn Fiellin, M.D., senior author, director of the Yale Center for Health and Learning Games, and associate professor at the Yale School of Medicine.

###

Other authors on this study include Brent A. Moore, Stephen R. Holt, Nathan Hansen, Tassos C. Kyriakides, Michael Virata, Sheldon Brown, Amy C. Justice, Kendall J. Bryant, and David A. Fiellin.

This study was funded by the U.S. National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism.

Aids and Behavior DOI: 10.1007/s10461-018-2241-z

Media Contact

Kendall Teare
[email protected]
203-836-4226
@yale

http://www.yale.edu

http://dx.doi.org/10.1007/s10461-018-2241-z

Share12Tweet8Share2ShareShareShare2

Related Posts

Evaluating Pediatric Emergency Care Quality in Ethiopia

February 7, 2026

TPMT Expression Predictions Linked to Azathioprine Side Effects

February 7, 2026

Improving Dementia Care with Enhanced Activity Kits

February 7, 2026

Decoding Prostate Cancer Origins via snFLARE-seq, mxFRIZNGRND

February 7, 2026
Please login to join discussion

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    57 shares
    Share 23 Tweet 14
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Evaluating Pediatric Emergency Care Quality in Ethiopia

TPMT Expression Predictions Linked to Azathioprine Side Effects

Improving Dementia Care with Enhanced Activity Kits

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.